Biopharmaceutical CMO Market Report 2026

The biopharmaceutical cmo market size has grown rapidly in recent years. It will grow from $28.02 billion in 2025 to $32.03 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing biologics pipeline development, expansion of clinical trial activity, rising demand for flexible manufacturing capacity, growth of biosimilar approvals, availability of specialized biomanufacturing expertise.

The biopharmaceutical cmo market size is expected to see rapid growth in the next few years. It will grow to $54.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing investments in advanced biologics, rising demand for rapid scale-up manufacturing, expansion of personalized therapies, growing adoption of continuous bioprocessing, increasing focus on risk-sharing manufacturing models. Major trends in the forecast period include increasing outsourcing of biologics manufacturing, rising demand for biosimilar production services, growing use of single-use bioprocessing systems, expansion of cell and gene therapy manufacturing, enhanced focus on end-to-end cmo capabilities.

The rising prevalence of chronic diseases is expected to drive the growth of the biopharmaceutical CMO market in the coming years. Chronic diseases are long-lasting health conditions that persist throughout a person's life, often developing gradually and requiring continuous medical care. Biopharmaceutical CMOs play a key role in combating chronic diseases by accelerating drug development, providing cost-effective production, and maintaining high-quality standards, thereby improving the accessibility and affordability of essential medications. For example, in January 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that the burden of noncommunicable diseases - primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes - continues to rise, causing 41 million deaths annually, which accounts for 74% of all deaths and the majority of premature mortality worldwide, with the most significant impact in low- and middle-income countries. Consequently, the growing burden of chronic diseases is driving the biopharmaceutical CMO market.

Major companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to develop innovative biopharmaceutical products. Such partnerships enable biopharmaceutical CMO companies to combine resources and expertise, strengthen research and development capabilities, expand market presence, and accelerate commercialization, ultimately fostering innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a Netherlands-based contract manufacturing company, partnered with AGC Biologics, a US-based contract development and manufacturing company. Through this collaboration, they aim to provide a streamlined, comprehensive solution for biopharmaceutical development and manufacturing, shortening timelines and simplifying processes for drug developers.

In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed sum. The acquisition aims to strengthen WACKER’s biotechnology operations and expand fermentation capacities for sustainably produced food ingredients, supporting its future growth plans. ADL BioPharma, based in Spain, is a contract manufacturing company specializing in the development and production of high-quality fermentation products.

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG.

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceutical cmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biopharmaceutical cmo market by increasing costs of imported bioreactors, filtration systems, single-use consumables, analytical instruments, and packaging materials. CMOs in North America and Europe are most affected due to reliance on global supplier networks, while Asia-Pacific faces higher export-related cost pressures. These tariffs are increasing manufacturing costs and influencing contract pricing structures. However, they are also encouraging local equipment sourcing, regional capacity expansion, and investment in vertically integrated biomanufacturing facilities.

The biopharmaceutical cmo market research report is one of a series of new reports that provides biopharmaceutical cmo market statistics, including biopharmaceutical cmo industry global market size, regional shares, competitors with a biopharmaceutical cmo market share, detailed biopharmaceutical cmo market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical cmo industry. This biopharmaceutical cmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A biopharmaceutical CMO is a business that offers manufacturing services, capable of producing small quantities for preclinical research and development as well as larger volumes required for clinical trials and commercialization. The biopharmaceutical CMO helps reduce overall operational risk and shortens time to market.

The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics are used to produce a wide range of products derived from human, animal, or microbial sources as medicinal biologics. Biologics are substances made from living organisms or contain components of them. Vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins are examples of biologic medications. Biopharmaceutical CMO products originate from various sources, including mammalian and non-mammalian. Biopharmaceutical CMO services encompass manufacturing, fill-and-finish operations, analytical and quality control studies, and packaging.

The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.